AMPK-induced novel phosphorylation of RUNX1 inhibits STAT3 activation and overcome imatinib resistance in chronic myelogenous leukemia (CML) subjects

Imatinib resistance remains an unresolved problem in CML disease. Activation of JAK2/STAT3 pathway and increased expression of RUNX1 have become one reason for development of imatinib resistance in CML subjects. Metformin has gained attention as an antileukemic drug in recent times. However, the mol...

Descripción completa

Detalles Bibliográficos
Autores principales: Gayatri, Meher Bolisetti, Kancha, Rama Krishna, Behera, Abhayananda, Patchva, Dorababu, Velugonda, Nagaraj, Gundeti, Sadasivudu, Reddy, Aramati Bindu Madhava
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10616083/
https://www.ncbi.nlm.nih.gov/pubmed/37903788
http://dx.doi.org/10.1038/s41420-023-01700-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10616083/
https://www.ncbi.nlm.nih.gov/pubmed/37903788
http://dx.doi.org/10.1038/s41420-023-01700-x

Ejemplares similares